Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib, Sintilimab, and Capecitabine in Previously Treated Metastatic Small Bowel and Appendiceal Adenocarcinoma
NCT05472948Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in small bowel adenocarcinoma (SBA), Appendiceal carcinoma, sponsored by Sun Yat-sen University. Started Feb 2023; status: recruiting.
02
Drugs
surufatinib
03
Conditions
small bowel adenocarcinoma (SBA)Appendiceal carcinoma
Beyond the preview
Go deeper on NCT05472948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472948.